Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study

BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Donald B., Berry-Kravis, Elizabeth, Wheeler, Anne, Raspa, Melissa, Merrien, Florence, Ricart, Javier, Koumaras, Barbara, Rosenkranz, Gerd, Tomlinson, Mark, von Raison, Florian, Apostol, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743124/
https://www.ncbi.nlm.nih.gov/pubmed/26855682
http://dx.doi.org/10.1186/s11689-015-9134-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743124/
https://www.ncbi.nlm.nih.gov/pubmed/26855682
http://dx.doi.org/10.1186/s11689-015-9134-5

Ejemplares similares